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Abstract 
Background: Apolipoprotein E-deficient (ApoE−/−) rodents spontaneously develop severe hypercholesterolemia 
and increased aortic stiffness, both accepted risk factors for cardiovascular morbidity and mortality in humans. In 
patients with resistant hypertension renal denervation (RDN) may improve arterial stiffness, however the underlying 
mechanisms are incompletely understood. This study investigates the impact of RDN on aortic compliance in a novel 
atherosclerosis prone ApoE−/−-rat model.
Methods: Normotensive, 8 weeks old ApoE−/− and Sprague–Dawley (SD) rats were subjected to bilateral surgical 
RDN (n = 6 per group) or sham operation (n = 5 per group) and fed with normal chow for 8 weeks. Compliance of 
the ascending aorta was assessed by magnetic resonance imaging. Vasomotor function was measured by aortic ring 
tension recordings. Aortic collagen content was quantified histologically and plasma aldosterone levels were meas-
ured by enzyme-linked immunosorbent assay (ELISA).
Results: After 8 weeks, ApoE−/−-sham demonstrated a 58 % decrease in aortic distensibility when compared with 
SD-sham (0.0051 ± 0.0011 vs. 0.0126 ± 0.0023 1/mmHg; p = 0.02). This was accompanied by an impaired endothe-
lium-dependent relaxation of aortic rings and an increase in aortic medial fibrosis (17.87 ± 1.4 vs. 12.27 ± 1.1 %; 
p = 0.006). In ApoE−/−-rats, RDN prevented the reduction of aortic distensibility (0.0128 ± 0.002 vs. 0.0051 ± 0.0011 
1/mmHg; p = 0.01), attenuated endothelial dysfunction, and decreased aortic medial collagen content (12.71 ± 1.3 
vs. 17.87 ± 1.4 %; p = 0.01) as well as plasma aldosterone levels (136.33 ± 6.6 vs. 75.52 ± 8.4 pg/ml; p = 0.0003). Car-
diac function and metabolic parameters such as hypercholesterolemia were not influenced by RDN.
Conclusion: ApoE−/−-rats spontaneously develop impaired vascular compliance. RDN improves aortic distensibility 
and attenuated endothelial dysfunction in ApoE−/−-rats. This was associated with a reduction in aortic fibrosis forma-
tion, and plasma aldosterone levels.
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Background
The ability of the arterial system to adapt to changes in 
mechanical demands depends on its vascular compliance. 
Compliance describes the amount of volume change of 
blood vessels following a given (blood) pressure change 
[1]. Hyperlipidemia can induce remodeling processes of 
the arterial wall, thereby impairing vascular compliance 
[2–4]. The underlying molecular mechanisms contribut-
ing to impaired vascular compliance are multifactorial 
and may involve increased sympathetic nerve activity 
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activation, enhanced vascular oxidative stress, and over-
expression of inflammatory molecules [4–8].
Renal denervation (RDN) has been shown to reduce 
blood pressure (BP) in animal models and in cer-
tain patients with uncontrolled hypertension [9–12]. 
Recent studies have demonstrated that RDN may also 
exhibit additional systemic effects in parallel to BP 
lowering [13, 14], including improvement in arterial 
stiffness [15]. In obese, spontaneously hypertensive 
rats (SHR-ob), RDN inhibited progressive BP increase 
in SHR-ob and suppressed progression of kidney 
injury, cardiac fibrosis, and left ventricular dysfunc-
tion [16]. In goats with persistent atrial fibrillation 
(AF), RDN reduced atrial sympathetic nerve sprouting, 
structural alterations, and AF complexity [17]. In nor-
motensive ApoE-deficient mice, fed with Western-type 
diet, RDN attenuated atherosclerotic lesion formation 
at the aortic root without affecting hyperlipidemia 
[18].
The effect of RDN on the development of aortic remod-
eling and impairment of vascular compliance under 
hyperlipidemic conditions yet at a preatherosclerotic 
stage has not yet been investigated systematically. To 
assess the role of the sympathetic nervous system and 
its modulation by RDN, we used a novel, normoten-
sive ApoE-deficient rat model of hypercholesterolemia 
[19] with a hitherto uncharacterized cardiovascular 
phenotype.
Methods
All chemicals used were purchased from Carl Roth 
GmBH  +  Co.KG (Karlsruhe, Germany) unless men-
tioned otherwise.
Animals
The animal experiments were conducted in accord-
ance with “The guide for the Care and Use of labora-
tory Animals” published by the US National Institutes 
of Health (NIH Publication No. 85-23, revised 1996) 
and approved by the local animal ethics committee 
(Landesamt für Verbraucherschutz, Amtstierärztlicher 
Dienst, Lebensmittelüberwachung Zentralstelle, Saar-
brücken, Germany. Nr.: 38/2012). Male ApoE-deficient 
rats (#TGRA3710HM4-1EA; ApoE−/−, n = 11), and their 
littermate controls Sprague–Dawley (SD, n =  11), were 
purchased from Sigma-Aldrich-SAGE Labs (Boyertown, 
USA) at an age of 7  weeks. The animals were housed 
individually in standard cages and received standard 
chow diet (Ssniff® standard diet #V1536, Ssniff® Spezial-
itäten GmbH, Soest, Germany) and tap water ad libitum. 
At an age of 8  weeks the animals were randomized to 
either RDN or sham operation and sacrificed at an age of 
16 weeks. Blood pressure (BP) and heart rate (HR) were 
measured non-invasively by a computerized tail-cuff sys-
tem (BP-2000 Visitech Systems, USA).
It is known from ApoE-deficient mice that usage of 
high-fat, high-cholesterol Western-type diet accelerated 
the progression of atherosclerosis [18, 20]. In ApoE−/−-
rats, we observed that administration of a Western-type 
diet containing 0.3  % cholesterol resulted in increased 
mortality after 2–3 weeks, most likely due to severe fatty 
degeneration of the liver (Additional file  1: Figure S1). 
Therefore, we resigned from feeding ApoE−/−-rats with 
Western-type diet and focused on preatherosclerotic aor-
tic remodeling in hyperlipidemic ApoE−/−-rats at an age 
of 16 weeks fed with standard chow [19].
Renal denervation and sham operation
RDN in rats was performed as described previously 
[16]. Six ApoE−/− and six SD rats (ApoE−/−-RDN and 
SD-RDN, respectively) underwent RDN at the age of 
8 weeks. In brief, rats were anesthetized with 1.5–2.5 % 
isoflurane (AbbVie #B506, Ludwigshafen, Germany) and 
both kidneys were surgically denervated by cutting all 
visible nerves in the area of the renal hilus and by strip-
ping approximately 2–4  mm of the adventitia from the 
renal artery and moistening with a 20 % phenol/ethanol 
solution. Another five ApoE−/− and five SD rats were 
submitted to a surgical sham procedure with kidney 
exposition but without RDN, serving as sham controls 
(ApoE−/−-sham and SD-sham, respectively). At an age 
of 16 weeks, rats were sacrificed and reductions in renal 
tissue norepinephrine (NE) concentrations were deter-
mined by high-performance liquid chromatography to 
assess the effectiveness of RDN.
Magnetic resonance imaging
All MRI experiments were performed using a 9.4 Tesla 
horizontal bore animal scanner (Bruker BioSpin 94/20, 
Ettlingen, Germany) with a 2  ×  2 phased-array surface 
coil. All animals were subjected to general anesthesia 
using a mixture of isoflurane and oxygene (2  %/98  %) 
applied by a dedicated nose mask at a flow rate of 1.5  l/
min. A retrospectively self-gated black blood sequence 
(IntraGate FLASH, TR 8.9 ms, TE 2.1 ms, flip angle 10°, 
field of view 4.5 × 4.5 cm, matrix 384 × 384, slice thick-
ness 1 mm, pixel size 117 × 117 μm2) was acquired per-
pendicular to the ascending aorta at the level of the right 
pulmonary artery. 25 cine frames were reconstructed 
from the acquired raw data in order to display one car-
diac cycle. In addition, retrospectively self-gated bright 
blood cine sequence were acquired in short axis orien-
tation covering the left ventricle from base to apex with 
reconstruction of 20 cine frames for every dedicated slice 
position (IntraGate FLASH, TR 5.6  ms, TE 1.5  ms, flip 
angle 12°, field of view 4.0 × 4.0 cm, matrix 256 × 256, 
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slice thickness 1 mm, pixel size 156 × 156 μm2). For fur-
ther quantitative analyses, the image data were trans-
ferred to an external workstation and evaluated using 
image evaluation software (OsiriX®, Pixmeo, Bernex, 
Switzerland).
For the assessment of aortic distensibility the cross sec-
tional vessel area of the ascending aorta was measured by 
manual contouring at the blood/vessel wall interface at 
end-diastole (ED) and end-systole (ES).
Aortic distensibility (AD) was calculated with
Left ventricular end diastolic volume (LVEDV) and the 
left ventricular end systolic volume (LVESV) were evalu-
ated by manual contouring of the blood/subendocardial 
myocardium.
Stroke volume (SV) and ejection fraction (EF) were cal-
culated with:
Histology
Aortic medial collagen content
Thoracic aorta was sectioned (10  μm) on a Leica cry-
ostat at  −25  °C (Kryostat Leica CM 1900-V5.0, Leica 
Microsystems, Nussloch, Germany). Sections were 
stained with Picro-Sirius Red (Morphisto®, Frankfurt, 
Germany) to visualize collagen fibers. The percentage of 
the media consisting of interstitial collagen was calcu-
lated as the ratio of Picro-Sirius-Red positively stained 
area over total aortic medial-tissue area. For the analy-
sis Nicon Instruments Software (NIS)-Elements (BR 3.2, 
Nikon instruments, USA) was used.
Ficoll‑isolation of mononuclear cells
Peripheral blood mononuclear cells (MNCs) were iso-
lated by the use of a Ficoll density gradient within 30 min 
after collecting peripheral arterial blood from all animals. 
Whole citrate blood was mixed 1:1 (v/v) with a solution 
of phosphate-buffered saline (PBS) and layered onto 0.25 
Vol. of Ficoll (Biochrom GmbH, Berlin, Germany). After 
centrifugation at 800g for 20  min at room temperature, 
the layer of mononuclear cells was collected and stored 
immediately for RNA isolation.
Gene expression
Reverse Transcription: RNA was prepared from rat 
aortic-tissue and mononuclear cells using peqGold Tri-
Fast (PeqLab, Erlangen, Germany) extraction reagent 
per manufacturer’s protocol. For cDNA preparation 
2  μg of RNA were digested with DNAse (Peqlab) than 
AD = (Area (ES) − Area (ED)/
(Area (ED)× pulse pressure (PP)),
SV = LVEDV−LVESV
EF = SV/LVEDV
reversely transcribed using the HighCap cDNA RT Kit 
(Applied Biosystems, Darmstadt, Germany) according 
to the manufacturer´s protocol. TaqMan PCR was con-
ducted in a StepOne plus thermocycler (Applied Bio-
systems) using TaqMan GenEx Mastermix (Applied 
Biosystems, #4369016). Signals were normalized to cor-
responding glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) controls. No template controls were used to 
monitor for contaminating amplifications. The ΔCt was 
used for statistical analysis and 2−ΔΔCt for data presenta-
tion. Probes used to amplify the transcripts were as fol-
lows (Applied Biosystems): TNFα (Rn01525859_g1); 
IL1β (Rn00580432_m1); IL6 (Rn01410330_m1); GAPDH 
(Rn99999916_s1), ICAM1 (Rn00564227_m1), VCAM1 
(Rn00563627_m1); eNOS (Rn02132634_s1).
Enzyme linked immunosorbent assays (ELISA)
Plasma concentrations of aldosterone, angiotensin II, IL6 
and IL1β were determined by ELISA, using Enzo Aldos-
terone EIA Kit (ADI-900-173; Lausen, Switzerland), Enzo 
Angiotensin II ELISA Kit (ADI-900-204; Lausen, Switzer-
land), Rat IL6 ELISA Kit (R&D systems, Abington, UK) 
and Cloud IL1β Immunoassay (Cloud-Clone Corp. Hou-
ston, TX, USA) following the manufacturer’s protocol. For 
analysis of renal renin and angiotensin II tissue concentra-
tions, 10 mg kidney of each rat was homogenized in 600 µl 
PBS, containing 1 % Triton-X and complete protease inhib-
itors (Roche Diagnostics GmbH, Mannheim, Germany), 
followed by centrifugation at 18000g for 5 min. Angioten-
sin II and renin levels were measured from the supernatant 
by ELISA using Elabscience ELISA Kit (WuHan, Peoples 
Republic of China) following the manufacturer’s protocol.
Determination of renal norepinephrine content
Kidney tissue from rat was minced thoroughly in TRIS-
EDTA buffer (in mmol/l: 5.0 Tris(hydroxymethyl)ami-
nomethane, 2.0 Na-EDTA, pH 7.4). After centrifugation, 
supernatant was used to analyze NE content by high 
pressure liquid chromatography (HPLC) using Chro-
mosystems catecholamine Kit for HPLC (Chromsystems 
Instruments & Chemicals GmbH, Munich, Germany) 
following the manufacturer’s protocol.
Aortic ring preparation and tension recording
Aortic ring tension was measured as described previously 
[20]. After excision, the thoracic aorta was immersed in 
Tyrode’s solution containing (in mmol/l) 118.0 NaCl, 2.5 
CaCl2, 4.73 KCl, 1.2 MgCl2, 1.2 KH2PO4, 25.0 NaHCO3, 
0.026 Na-EDTA, and 5.5 d-(+)-glucose, pH 7.4. Adven-
titial tissue was carefully removed. Three-millimeter 
aortic rings (n = 4 rings per animal with n = 5 animals 
per group) were mounted in organ bath chambers filled 
with the Tyrode’s solution (37  °C; aerated with 95 % O2 
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and 5  % CO2) and were attached to a force transducer 
recording isometric tension (Model 750TOBS, Danish 
Myo Technology (DMT), Aarhus, Denmark). Aortic rings 
were stretched to a resting tension of 10 mN, which was 
maintained throughout the experiment. Pharmacologi-
cally induced contraction of aortic rings was performed 
with phenylephrine (5  μmol/l; Sigma-Aldrich, Stein-
heim, Germany). After a plateau was reached, increasing 
concentrations of carbachol (carbamylcholine chloride; 
1  nmol/l–100  μmol/l; Sigma-Aldrich) were added to 
obtain cumulative concentration—response curves to 
study endothelium-dependent relaxation. The relaxing 
effect of carbachol was abolished by adding N-nitro-l-ar-
ginine methyl ester (1  μmol/l; Sigma-Aldrich). To study 
endothelium-independent relaxation after a washout 
period, increasing concentrations of glyceryl trinitrate 
(100 nmol/l–10 µmol/l; Sigma-Aldrich) were added after 
a single dose of phenylephrine (5 µmol/l).
Aortic rings without any response to relaxation with 
carbachol or glyceryl trinitrate (<10  % relaxation) were 
excluded from statistical analysis. Relaxation response 
was expressed as percentage of phenylephrine-induced 
pre-contraction. The concentration of drugs used to 
achieve 50  % of the maximal response (logEC50) was 
determined by using nonlinear regression analysis 
(GraphPad Prism 6, San Diego, CA, USA).
Statistics
Data are presented as mean ± SEM and differences were 
tested for significance using an unpaired Student’s t test, 
one-way-ANOVA with Tukey’s multiple comparisons 
test or two-way-ANOVA with Bonferroni multiple com-
parisons test when appropriate. A p value of less than 
0.05 was considered statistically significant. Statistical 
analysis was performed using GraphPad Prism 6.
Results
Renal norepinephrine content, cardiac function, 
and metabolic parameters
Eight weeks after RDN-procedure, renal NE concentra-
tions were significantly lower in SD-RDN and ApoE−/−-
RDN, when compared to their respective sham-operated 
controls (Fig. 1), confirming successful renal nerve abla-
tion. Table 1 depicts parameters of cardiac function and 
serum chemistry eight weeks after RDN- or sham inter-
vention. Body weight, heart weight, systolic and diastolic 
blood pressure, heart rate, stroke volume, ejection frac-
tion, left ventricular systolic, and diastolic volume did 
not differ between ApoE−/−-sham and SD-sham, demon-
strating that at an age of 16 weeks ApoE−/−-rats remain 
normotensive. Blood pressure did not differ between 
ApoE−/− and SD rats at the age of 8  weeks. Total cho-
lesterol, low-density lipoprotein (LDL), and triglycerides 
were significantly higher in ApoE−/−-rats, while high-
density lipoprotein (HDL) was significantly lower. RDN 
had no influence on myocardial function or metabolic 
parameters.
RDN improved aortic distensibility and attenuated 
progression of endothelial‑dependent dysfunction
At an age of 16  weeks, ApoE−/−-sham rats exhib-
ited a significantly reduced aortic distensibility com-
pared with age-matched SD-rats (0.0051  ±  0.0011 
vs.  0.0126  ±  0.0023  1/mmHg; p  =  0.02), as measured 
by MRI with high-resolution cine sequences acquired 
at 9.4 Tesla. ApoE−/−-rats also demonstrated an age-
dependent reduction of aortic distensibility, comparing 
baseline values at an age of 8 weeks (0.0138 ± 0.0039 1/
mmHg) and final measurements at an age of 16  weeks 
(0.0051  ±  0.0011  1/mmHg; p  =  0.07). Lack of statisti-
cal significance might by due to the limited number of 
animals.
In ApoE−/−-RDN rats, reduction of aortic distensibil-
ity was prevented (0.0128  ±  0.002 (1/mmHg; p  =  0.01 
vs. ApoE-sham) and equals values of SD-sham rats 
(Fig.  2a, b). Endothelial relaxation of aortic rings was 
tested in organ bath experiments at an age of 16 weeks. 
Efficacy of endothelium-dependent vascular response to 
increasing concentrations of carbachol was significantly 
impaired in ApoE−/−-sham compared with SD-sham. In 
ApoE−/− receiving RDN, vasorelaxation improved when 
compared with ApoE−/−-sham animals (Fig.  3a). Calcu-
lation of the maximal response (Emax) and half-maximal 
dose (logEC50) to Carbachol also demonstrated a reduced 
Renal tissue
norepinephrine












Fig. 1 Effect of RDN on renal norepinephrine content. Kidney tis-
sue norepinephrine (NE) content of ApoE−/− rats and SD controls, 
8 weeks after RDN- (n = 6 per group) or sham-operation (n = 5 per 
group). Values are mean ± SEM. **p > 0.01
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response of the endothelium in ApoE−/−-sham com-
pared to SD-sham. However, RDN-treatment of ApoE−/− 
failed to reach significant improvement of endothelial 
relaxation using linear regression calculation (Table  2). 
Endothelium-independent relaxation induced by glyceryl 
trinitrate did not significantly differ between the groups 
(Fig. 3b). Emax and logEC50 of glyceryl trinitrate did also 
not differ among the groups (Table 2).
Additionally, we analyzed mRNA expression pattern of 
endothelial nitric oxide synthase (eNOS) in aortic tissue of 
ApoE−\− and SD rats. Levels of mRNA were not differen-
tially regulated between the groups and RDN had no effect 
on eNOS gene expression (Additional file 1: Table S1).
Effect of RDN on RAAS activation and inflammatory 
response
Plasma aldosterone concentration was significantly 
increased in ApoE−/−-sham compared with SD-sham 
(136.33 ± 6.6 vs. 88.83 ± 15.4 pg/ml; p = 0.02). Enhanced 
aldosterone release was inhibited following RDN in 
ApoE−/− (75.52 ± 8.4 pg/ml; p = 0.0003 vs. ApoE-sham), 
but not in SD-RDN (99.17 ± 12.2 pg/ml; p = 0.60 vs. SD-
sham) (Fig.  4a). AngII plasma level was not changed in 
ApoE−/−-sham compared with SD-sham (25.26  ±  6.2 
vs. 14.92 ± 2.3 pg/ml; p = 0.15) and RDN-treatment did 
not significantly reduce AngII plasma level neither in 
ApoE−/−-RDN (17.51  ±  4.1  pg/ml; p  =  0.07 vs. ApoE-
sham) nor in SD-RDN (9.82  ±  1.4  pg/ml; p  =  0.08 vs. 
SD-sham). Renal tissue concentration of renin and AngII 
did not differ between sham-operated rats, however RDN 
resulted in a significant reduction of renin and AngII-tis-
sue level in ApoE−/−-RDN and SD-RDN (Fig. 4b).
In circulating mononuclear cells, gene expres-
sion of TNFα and IL6 was significantly increased in 
ApoE−/−-sham compared with SD-sham, while IL1β was 
unchanged. RDN significantly inhibited transcriptional 
enhancement of TNFα and IL6 in ApoE−/−, but had 
no effect on IL1β mRNA-levels (Fig.  4c). Plasma levels 
of IL6 and IL1β were significantly higher in ApoE−/−-
sham compared to SD-sham (IL6: 157.06  ±  6.54 vs. 
123.78  ±  4.39  pg/ml, p  <  0.01; IL1β: 177.41  ±  8.77 vs. 
65.75 ± 15.32 pg/ml, p < 0.01) demonstrating increased 
inflammation in ApoE−/− rats. Modulation of the sym-
pathetic nervous system by RDN had no effect on IL6 or 
IL1β plasma concentration, neither in SD-RDN nor in 
ApoE−/−-RDN (Additional file 1: Table S1).
In aortic tissue of ApoE−/−-sham, IL1β mRNA-levels 
were elevated in comparison to SD-sham (relative gene 
Table 1 Body weight, blood pressure and metabolic parameters 8 weeks after RDN
Values are mean ± SEM
LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, GPT glutamat-pyruvat-transaminase, GOT glutamat-oxalacetat-transaminase, 
HDL high-density lipoprotein, LDL low-density lipoprotein
* p < 0.05 SD-RDN vs. ApoE−\−-RDN
§ p < 0.01 SD-sham vs. ApoE−\−-sham
# p < 0.01 SD-RDN vs. ApoE−\−-RDN (one-way-Anova followed by Tukey´s multiple comparisons test)
SD‑sham n = 5 SD‑RDN n = 6 ApoE−/−‑sham n = 5 ApoE−/−‑RDN n = 6
Body weight (g) 456.2 ± 25.64 474.14 ± 11.26 446.75 ± 3.68 456.2 ± 10
Heart weigth (g) 1.41 ± 0.04 1.45 ± 0.05 1.51 ± 0.06 1.45 ± 0.04
Heart rate (bpm) 360 ± 9 370 ± 10 341 ± 13 359 ± 7
Blood pressure (mmHg)
 Systolic 144 ± 5 137 ± 4 148 ± 12 136 ± 7
 Diastolic 116 ± 4 109 ± 10 121 ± 11 99 ± 8
 Stroke volume (µl) 210 ± 10 219 ± 5 203 ± 10 224 ± 9
 Ejection fraction (%) 61 ± 3 61 ± 1 59 ± 2 60 ± 2
 LVEDV (µl) 342 ± 11 357 ± 11 344 ± 8 372 ± 13
 LVESV (µl) 131 ± 12 137 ± 8 140 ± 11 148 ± 10
Serum chemistry
 GPT (U/l) 79.64 ± 7.53 70.5 ± 5.91* 109.66 ± 14.96 104.43 ± 10.26
 GOT (U/l) 178.36 ± 24.74 169.64 ± 13.83 222.22 ± 33.31 217.28 ± 32.1
 Creatinine (mg/dl) 0.306 ± 0.02 0.33 ± 0.01 0.33 ± 0.02 0.29 ± 0.03
 Glucose (mg/dl) 235.2 ± 8.24 268.71 ± 17.18 328.25 ± 28.51 289.33 ± 25.65
 Cholesterol (mg/dl) 48.2 ± 3.28§ 45.71 ± 3.21# 131.5 ± 17.54 152.5 ± 13.63
 Triglycerides (mg/dl) 30.6 ± 7.04§ 30.57 ± 8.05# 152.2 ± 27.41 152.5 ± 18.44
 LDL (mg/dl) 10.96 ± 1.15§ 10.5 ± 0.94# 52.3 ± 6.62 65.28 ± 9.61
 HDL (mg/dl) 37.58 ± 1.36§ 34.93 ± 3.36# 11.7 ± 1.67 15.78 ± 1.81
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expression/GAPDH: 2.55 ± 0.3 vs. 1.15 ± 0.2; p = 0.02), 
while transcription of TNF and pro-atherosclerotic inter-
cellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule  1 (VCAM-1) were unchanged. RDN 
could neither attenuate inflammatory nor pro-athero-
sclerotic gene expression (Additional file 1: Table S1).
Morphological analysis of the thoracic aortic wall
In 16  weeks old ApoE−/− and SD rats, microscopic 
analysis of the aorta showed no detectable atheroscle-
rotic plaque formation in the open luminal surface after 
staining with Oil-red O, and no visible fragmentation 
of elastin fibers after staining with Elastin van Gieson 
(Additional file 1: Figure S2). However, Sirius-red stain-
ing demonstrated an increased amount of interstitial 
fibrosis in the aortic media of ApoE−/−-sham compared 
with SD-sham (Fig.  5a). Collagen content was signifi-
cantly lower in ApoE−/−-RDN compared with ApoE−/−-
sham (Fig.  5b). Wall thickness of the aortic media, 
Fig. 2 Effect of RDN on aortic distensibility and vasorelaxation. a Quantification of aortic distensibility at baseline (n = 6 per group), and 8 weeks 
after RDN procedure (n = 6 per group) or sham operation (n = 5 per group). Data are based on in vivo measurements of cross section vessel areas. 
b Representative example of high-resolution black blood cine MRI perpendicular to the ascending aorta. The bar on the right side indicates 5 mm. 
The circle depicts the cross sectional vessel area of the ascending aorta (arrow). The arrowhead points to the superior caval vein. ED end diastole, 
ES end systole. Values are mean ± SEM. SD baseline vs. SD-sham, p = 0.51 (n.s.); SD-sham vs. SD-RDN, p = 0.23 (n.s.); ApoE−/− baseline vs. ApoE−/−-
sham, p = 0.07 (n.s.); *p < 0.05, **p < 0.01
Fig. 3 Effect of RDN on endothelial function. a Endothelium-
dependent vasorelaxation of aortic rings in response to carbachol 
and b endothelium-independent relaxation in response to glyceryl 
trinitrate in 16 weeks old SD-sham, SD-RDN, ApoE−/−-sham and 
ApoE−/−-RDN rats. Values are mean ± SEM. §p < 0.001 SD-RDN vs. 
ApoE−\−-RDN and ApoE−\−-sham; ψp < 0.001 SD-sham vs. ApoE−\−-
RDN;#p < 0.01 SD-sham vs. ApoE−\−-RDN; θp < 0.001 SD-sham vs. 
ApoE−\−-sham; *p < 0.01 ApoE−\−-RDN vs. ApoE−\−-sham (two-way-
Anova followed by Bonferroni multiple comparison test)
Table 2 Maximal relaxation (Emax) and  half-maximal dose 
(logEC50) in  response to  carbachol and  glyceryl trinitrate 
in 16 weeks old rats
Values are mean ± SEM. p values were calculated using one-way-Anova 
followed by Tukey´s multiple comparisons test
§ p = 0.01 SD-sham vs. ApoE−\−-sham




Number of rats 5 5 5 5
Response to carbachol
 Emax, (%) 67 ± 6.0 73 ± 3.3 43 ± 4.8§ 53 ± 4.9
 logEC50 (log M) −6.22 ± 0.06 −6.17 ± 0.03 −5.81 ± 0.15 −5.88 ± 0.12
Response to glyceryl trinitrate
 Emax, (%) 232 ± 24 237 ± 6 209 ± 13 217 ± 16
 logEC50 (log M) −6.5 ± 0.10 −6.47 ± 0.08 −6.32 ± 0.06 −6.29 ± 0.10
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assessed by hematoxylin-eosin staining, was unchanged 
in ApoE−/−-sham compared to SD-sham (124 ±  9.8 vs. 
105 ± 1.7 µm; p = 0.13), and was not influenced by RDN 
(SD-RDN: 103 ± 5.8 µm; ApoE−/−-RDN: 113 ± 7.3 µm; 
Additional file 1: Figure S2).
Discussion
The sympathetic nervous system (SNS) is involved in 
the induction and progression of multiple cardiovas-
cular pathologies such as vascular damage [7, 8], atrial 
fibrillation [14], increased heart rate [21], and hyper-
tension [22]. Modulation of the SNS by RDN has been 
shown to reduce BP in certain patients with uncontrolled 
hypertension [9–12]. Recent studies have demonstrated 
that RDN may also exhibit additional systemic effects, 
occurring either in combination with blood-pressure 
lowering [13, 14], such as improvement of arterial stiff-
ness in patients with hypertension [15], or being partly 
independent of blood pressure changes [16–18]. The 
underlying mechanisms of these beneficial effects on 
vascular compliance are currently incompletely under-
stood. The present study therefore aimed to further elu-
cidate on the role of the SNS and its modulation by RDN 
on aortic remodeling and compliance in a atherosclerosis 
prone animal model of hyperlipidemia. We used a novel 
normotensive, hypercholesterolemic ApoE-deficient 
rat model [19], and demonstrated that these rats exhibit 
severely decreased aortic distensibility and an impaired 
vasorelaxation, already at a stage before atheroscle-
rotic lesions could be detected histologically in the aor-
tic sinus or the thoracic aorta. Our main findings are, 
that sympathetic modulation by surgical bilateral RDN 
improved aortic compliance and attenuated endothelial 
dysfunction. These improvements were associated with a 
decrease in circulating aldosterone levels, reduced aortic 
medial fibrosis formation, as well as a lower inflamma-
tory cytokine expression in circulating mononuclear cells 
(MNCs).
Fig. 4 Effect of renal denervation (RDN) on the renin-angiotensin-aldosterone system (RAAS) and on expression of inflammatory cytokines in 
isolated mononuclear cells. a Quantification of plasma aldosterone and angiotensin II. b Evaluation of renal tissue level of renin and angiotensin II 
c quantification of mRNA expression levels in mononuclear cells (MNCs) of IL1β, IL6 and TNFα in SD-sham (n = 5), SD-RDN (n = 6), ApoE−\−-sham 
(n = 5), ApoE−\−-RDN (n = 6). Values are mean ± SEM. Plasma aldosterone: SD-sham vs. SD-RDN, p = 0.60 (n.s.); Plasma angiotensin II: SD-sham vs. 
ApoE−/−-sham, p = 0.15 (n.s.); ApoE-sham vs. ApoE−/−-RDN, p = 0.07 (n.s.); SD-sham vs. SD-RDN, p = 0.08 (n.s.). Tissue renin SD-sham vs. ApoE−/−-
sham, p = 0.93 (n.s.). Tissue angiotensin II SD-sham vs. ApoE−/−-sham, p = 0.57 (n.s.). TNFα SD-sham vs. SD-RDN, p = 0.78 (n.s.); IL6 SD-sham vs. SD-
RDN, p = 0.91 (n.s.); IL1β SD-sham vs. SD-RDN, p = 0.86 (n.s.); ApoE−\−-sham vs. ApoE−\−-RDN, p = 0.87 (n.s.); SD-sham vs. ApoE−\−-sham, p = 0.14 
(n.s.); *p < 0.05, **p < 0.01; ***p < 0.001
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The renal SNS controls the renin secretion from the 
kidneys, thereby regulating the activity of the renin-
angiotensin-aldosterone system (RAAS). Renin release 
stimulates the generation of angiotensin II (AngII), and 
the release of aldosterone from the adrenal cortex [23]. 
AngII has been linked to structural alterations of the 
aortic wall, characterized by elastin deposition, increase 
in medial wall thickness, and vascular fibrosis forma-
tion [24], accompanied by an enhanced expression of 
inflammatory cytokines, which in the long-term result 
in vascular stiffness [4, 6, 24, 25]. Accordingly, blockade 
of AngII decreases medial wall thickness and vascular 
fibrosis [20, 24, 25]. Selective aldosterone receptor block-
ade by eplerenone has been shown to reduce atheroscle-
rosis and improve vasorelaxation in non-human primates 
fed with a high-cholesterol diet [26]. In ApoE−/− mice, 
administration of eplerenone prevented atherosclerosis 
progression without affecting serum cholesterol or tri-
glyceride levels [27]. This is in line with recent findings 
demonstrating that RDN decreases serum aldosterone 
and atherosclerotic lesion formation in the aortic roots 
of ApoE−/−-mice, independently of changes in BP [18]. 
Consistently with these reports, in the novel ApoE−/− rat 
model used herein, RDN reduced plasma aldosterone lev-
els and attenuated aortic medial fibrosis formation, while 
hyperlipidemia and cardiac parameters were not affected. 
Although RDN did not significantly influence blood 
pressure herein, it is conceivable that even a moderate 
decrease of BP may contribute to the herein observed 
improvements.
The aortic distensibility is codetermined by structural 
components of the arterial wall, i.e. extracellular matrix 
proteins [5, 28]. In the present study, ApoE−/− rats dem-
onstrated decreased aortic distensibility, associated with 
an increased aortic collagen content. This structural 
alteration was inhibited by RDN, preserving aortic dis-
tensibility, and emphasizes the influence of the SNS on 
aortic wall components. Vascular compliance, however, 
does not only depend on its wall composition, but also 
on endothelial function. Herein, modulation of the SNS 
by RDN positively influences endothelium-dependent 
relaxation which also might beneficially affect endothe-
lial function. Endothelial function also highly depends 
on nitric oxide (NO)-bioavailability, regulated by the 
endothelial NO synthase (eNOS) [29, 30]. In ApoE-mice 
fed with high-fat diet down-regulation of eNOS was asso-
ciated with impaired vascular function [20]. However, in 
our ApoE-deficient rat model, eNOS mRNA expression 
was not altered. It may also be conceivable, that local 
AngII mediates uncoupling of eNOS, thus decreasing 
total NO content and causing endothelial dysfunction 
[31]. The mechanisms regulation endothelial function are 
manifold and need to be further elucidated for this novel 
rat model.
Inflammation was also shown to initiate structural 
changes in the composition of the arterial wall, contrib-
uting to arterial stiffening [6, 32]. Several cytokines (e.g. 
IL1β, IL6, and TNFα) are known to stimulate the expres-
sion of ICAM-1 and VCAM-1, two important mole-
cules involved in the development of atherosclerosis [5, 
33]. In ApoE−/− rats, impaired vascular compliance was 
associated with an increased inflammatory response, 
probably influencing aortic distensibility by inducing vas-
cular remodeling processes. In the aorta of 16 weeks old 




















Fig. 5 Effect of RDN on aortic medial fibrosis content. a Repre-
sentative Sirius-red staining for determination of interstitial collagen 
content of the aortic media. b Quantification of collagen content 
in SD-sham (n = 5), SD-RDN (n = 5), ApoE−\−-sham (n = 5) and 
ApoE−\−-RDN (n = 5). Values are mean ± SEM. SD-sham vs. SD-RDN, 
p = 0.07 (n.s.); *p < 0.05; **p < 0.01
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up-regulated compared to SD rats, but transcription 
levels of TNFα, and pro-atherosclerotic ICAM-1 and 
VCAM-1 were not significantly increased, underpin-
ning the absence of atherosclerotic plaques in the aortic 
lumen. In isolated mononuclear cells (MNCs), mRNA 
expression of TNFα and IL6 was sensitive to RDN, and 
upregulation of these inflammatory marker genes could 
be inhibited. In contrast to MNCs, RDN did neither 
affect plasma levels of IL6 and IL1β nor gene expression 
of inflammatory cytokines in aortic tissue. Thus, in ath-
erosclerosis prone ApoE−/− rats, RDN failed to improve 
overall inflammatory activation, triggered by hypercho-
lesterolemia [34], but influenced activation of MNCs, 
while circulating interleukin levels and local aortic 
inflammatory activation was not modulated.
Conclusions
ApoE−/− rats fed with standard chow at an age of 
16 weeks develop impaired vascular compliance compa-
rable to other ApoE-deficient animal models [2, 20], yet 
at an atherosclerosis prone stage. Sympathetic modula-
tion by RDN prevented increasing aortic stiffening and 
positively effects endothelium-dependent relaxation in 
ApoE−/−, independently of alterations in BP and HR. 
These changes were associated with a reduction in aldos-
terone levels, and aortic fibrosis formation. Our data 
provide further evidence of the vital impact of the SNS 
in mediating vascular function and disease. The effects of 
SNS activation on vascular compliance are multifactorial. 
However, further experiments are needed to elucidate 
the involved pathways of the potential impact of RDN. At 
an age of 16 weeks hyperlipidemic ApoE−/− rats revealed 
decreased aortic distensibility, and impaired vasorelaxa-
tion, when fed with normal chow, thus providing a useful 
tool to study aortic compliance and vascular response at 
an atherosclerosis prone stage. Future studies are neces-
sary to assess whether catheter-based RDN also exhibits 
beneficial effects on vascular compliance in patients with 
and without hypertension.
Clinical perspective
Several clinical trials have demonstrated that catheter 
based RDN reduces blood pressure in certain patients 
with resistant hypertension [9–12]. In contrast, the 
recently published SYMPLICITY 3 trial showed no sig-
nificant difference in blood pressure between patients 
receiving sham treatment or RDN [35]. Reduction of 
afferent sympathetic nervous system activity and thereby 
central sympathetic activity may provide beneficial 
effects beyond lowering of blood pressure, including 
improvements in glucose tolerance [11], attenuation of 
the progression of atherosclerosis [18], reduction in left 
ventricular hypertrophy [36], and antiarrhythmic effects 
[17, 37]. Studies in a rat model of metabolic syndrome, 
bilateral RDN significantly reduced plasma renin activity, 
and prevented progression of kidney injury and cardiac 
remodeling [16]. Early trials in surgical sympathetectomy 
in severe hypertension documented reduced morbidity 
and mortality even in patients without blood pressure 
changes following the operation [38]. We provide pre-
clinical evidence suggestive of beneficial vascular effects 
associated with RDN, not exclusively related to altera-
tions in blood pressure.
Limitations
At an age of 16 weeks hypercholesterolemic ApoE−/− rats 
demonstrated elevated plasma aldosterone levels com-
pared to normocholesterolemic SD. This is in line with 
observations, that aldosterone production is sensitive 
to elevated low-density lipoprotein concentrations [39]. 
Herein, RDN did not affect plasma aldosterone concen-
trations in SD, but prevented a progressive increase in 
ApoE−/−, preserving aldosterone levels comparable to 
SD. The underlying mechanism remains speculative. In 
our normotensive rat model, renal tissue concentrations 
of NE, renin, and AngII did not differ between SD and 
ApoE−/−, and  RDN caused a similar decrease of these 
parameters in both SD and ApoE−/− without signifi-
cantly reducing blood pressure. This is in agreement with 
observations from Wang et al. [18], who documented sig-
nificantly reduced concentrations in serum aldosterone, 
renal NE, and plasma renin in normotensive ApoE−/− 
mice following RDN, however blood pressure and sys-
temic concentrations of NE, renin, and AngII remained 
unaffected [18]. Whether the decrease in plasma aldos-
terone levels occurs indirectly due to systemic regula-
tory adaptive changes or via additional beneficial effects 
remains unclear and deserves further studies.
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